Trial Profile

RESOLUTE-KOREA Registry - Registry to Evaluate the Efficacy of Zotarolimus-eluting Stent.

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 30 Sep 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zotarolimus (Primary)
Indications Coronary artery disease; Coronary artery restenosis
Focus Therapeutic Use
Acronyms RESOLUTE-KOREA

Most Recent Events

30 Aug 2017 Results comparing biodegradable-polymer biolimus A9-eluting stents and durable polymer drug-eluting stents from this and other registries in Korea, presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
26 Aug 2009 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com